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Transient Receptor Potential Vanilloid 4 (TRPV4)
Is Downregulated in Keratinocytes in Human
Non-Melanoma Skin Cancer
Camilla Fusi1,3, Serena Materazzi1,3, Daiana Minocci1, Vincenza Maio2, Teresa Oranges2, Daniela Massi2 and
Romina Nassini1
A subgroup of the transient receptor potential (TRP) channels, including vanilloid 1 (TRPV1), TRPV2, TRPV3,
TRPV4, and TRP ankyrin 1 (TRPA1), is expressed in cutaneous peptidergic somatosensory neurons, and has been
found in skin non-neuronal cells, such as keratinocytes. Different cancer cells express TRPs, where they may exert
either pro- or antitumorigenic roles. Expression and function of TRPs in skin cancers have been, however, poorly
investigated. Here, we have studied the distribution and expression of TRPs by immunohistochemistry and
messenger RNA (mRNA) in human healthy skin and human keratinocytic tumors, including intraepidermal
proliferative disorders (solar keratosis (SK) and Bowen’s disease), and non-melanoma skin cancer (NMSC; basal
cell and squamous cell carcinomas). Similar TRPV1, TRPV2, and TRPV3 staining was found in keratinocytes from
healthy and tumor tissues. TRPA1 staining was increased solely in SK samples. However, the marked TRPV4
staining and TRPV4 mRNA expression, observed in healthy or inflamed skin, was abrogated both in premalignant
lesions and NMSC. In a human keratinocyte cell line (HaCaT), TRPV4 stimulation released IL-8, which in turn
downregulated TRPV4 expression. Selective reduction in TRPV4 expression could represent an early biomarker of
skin carcinogenesis. Whether the cytokine-dependent, autocrine pathway that results in TRPV4 downregulation
contributes to NMSC mechanism remains to be determined.
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INTRODUCTION
The superfamily of transient receptor potential (TRP) channels
encompasses six subfamilies, which are widely and differently
expressed in various tissues and organs where they mediate
pleiotropic functions in health and disease (Nilius et al.,
2007). A subgroup of channels defined as thermo-TRPs
because of their ability to sense changes in temperature are
localized to a subpopulation of peptidergic primary sensory
neurons where they transduce nociceptive signals by a
heterogenous variety of physicochemical stimuli and drive
neurogenic inflammatory responses (Geppetti and Holzer,
1996; Nilius et al., 2007). This subgroup of channels
includes vanilloid 1 (TRPV1, the capsaicin receptor), TRPV2,
TRPV3, and TRPV4, and TRP ankyrin 1 (TRPA1, the mustard
oil receptor; Nilius et al., 2007). Activators of thermo-TRP may
be summarized as follows: TRPV1 is activated by vanilloid
compounds (capsaicin, resiniferatoxin), noxious heat
(X43 1C), low pH, and certain eicosanoids (Caterina et al.,
1997; Tominaga et al., 1998; Ho et al., 2008); TRPV3 and
TRPV2 are activated by innocuous warm temperatures (32–
39 1C) and noxious high temperature (452 1C), respectively;
TRPV4 is activated by mild high temperature (424 1C) and by
hypoosmotic stimuli (Liedtke et al., 2000; Cheng et al., 2010);
and TRPA1 is activated by moderate low temperatures and a
large series of environmental irritants and reactive molecules,
including reactive oxygen species and their by-products
(Bautista et al., 2006; Eid et al., 2008; Materazzi et al.,
2008; Biro and Kovacs, 2009).
Apart from their more prominent expression in nociceptors,
thermo-TRPs may be expressed in non-nociceptive neurons
(Chen et al., 2013). More importantly, for the present study,
some thermo-TRPs are found in non-neuronal cells (Earley
et al., 2009; Nozawa et al., 2009; Nassini et al., 2012)
including skin cells (Atoyan et al., 2009; Sokabe et al.,
2010; Radtke et al., 2011). TRPV1 expression has been
identified in epidermal and hair follicle keratinocytes,
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dermal mast cells, sebaceous gland–derived sebocytes, and
dendritic cells (Stander et al., 2004; Bodo et al., 2005). TRPV2
has been found in keratinocytes (Axelsson et al., 2009) and
macrophages (Link et al., 2010), and TRPV3 has been found in
blood vessels (Earley et al., 2010) and keratinocytes (Cheng
et al., 2010). The presence of TRPV4 has been reported in
basal and suprabasal keratinocytes of healthy human skin
(Chung et al., 2003; Radtke et al., 2011), where its function
has been related to cell survival after skin exposure to noxious
heat. Additional functions have been suggested for TRPV4
localized to skin cells. TRPV4 has been defined as osmo- and
mechano-sensor for its contribution in responses to mechani-
cal and osmotic stimuli (Liedtke and Kim, 2005). In particular,
TRPV4 has been suggested to control the homeostasis of the
skin permeability barrier, as a sort of osmotic pressure detector
(Denda et al., 2007). More recently, a highly relevant evolu-
tionary function of TRPV4 has been proposed in mammalian
skin both at the physiological and pathophysiological levels.
Indeed, TRPV4 appears to contribute to UVB-induced
damage and to UVB-evoked pain behavior by increasing the
expression of the proalgesic/algogenic mediator endothelin-1
(Moore et al., 2013). TRPA1 has been found in keratinocytes
and in melanocytes, where it is activated by UVA irradia-
tion, and via this mechanism it may contribute to the
phototransduction process (Atoyan et al., 2009; Bellono
et al., 2013). Thus, TRPA1 may contribute to an extraneural
pathway of phototransduction, possibly contributing to a
spectrum of UV-activated TRPs, whereby TRPV4 is sensing
UVB and TRPA1 UVA (Bellono et al., 2013; Moore et al.,
2013).
Non-melanoma skin cancer (NMSC) encompasses basal cell
carcinoma (BCC) and squamous cell carcinoma (SCC), which
account for B80 and 20%, respectively, of the total tumor
burden (Weinstock, 1994). Both cancer subtypes originate
from the basal layer of the epidermis of the skin, but although
BCC is characterized by a slow-growing rate and poor meta-
static potential SCC shows opposite features, thus representing
the major cause of the deaths attributable to NMSC
(Weinstock, 1994). BCC and SCC occur primarily on
sun-exposed areas of the body and have been associated
with chronic sun and UV exposure (Kwa et al., 1992; Bowden,
2004). Accumulating evidence suggests that oxidative stress
and release of inflammatory mediators from epidermal cells
contribute to tumor development (Marnett, 2000; Bachelor
and Bowden, 2004; Perrotta et al., 2011). Change in
expression and identification of functions, relevant for tumor
progression, have been reported for TRP channels in different
types of cancer (Duncan et al., 2001; Tsavaler et al., 2001;
Bode et al., 2009; Oancea et al., 2009; Lehen’kyi et al., 2012;
Santoni et al., 2012). However, little information exists
regarding TRP channel expression and function in skin
tumors, and particularly in NMSC. Here, we show that
TRPV4 is markedly downregulated in both the premalig-
nant lesions of NMSC such as solar keratosis (SK) and
Bowen’s disease (BD), and in SCC and BCC. In addition,
TRPV4 in cultured keratinocytes is downregulated by cell
exposure to a variety of proinflammatory mediators, including
IL-8, which is released from keratinocytes upon TRPV4
stimulation.
RESULTS
Localization of TRP in human healthy skin
We first investigated, by immunohistochemistry, the expres-
sion of TRP proteins in human healthy skin. Staining for
TRPV1 was observed in the epidermis, basal, and suprabasal
epidermal keratinocytes (Figure 1). TRPV2 and TRPV3 staining
was detected in basal and suprabasal keratinocytes and
endothelial cells (Axelsson et al., 2009) (Figure 2a and b).
TRPV4 protein expression was diffusely observed in basal and
suprabasal epidermal keratinocytes, and it was also found in
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Figure 1. Localization of transient receptor potential vanilloid 1 (TRPV1) in human healthy and cancer skin tissues. Immunohistochemical localization
reveals TRPV1 protein staining in the epidermis, basal, and suprabasal epidermal keratinocytes. TRPV1 staining and semiquantitative analysis of skin samples
taken from patients suffering from solar keratosis (SK), Bowen’s disease (BD), squamous cell carcinoma (SCC), and nodular (Nod), superficial (Sup), and
sclerodermiform (Scl) basal cell carcinoma (BCC) do not show a significant difference in protein expression in atypical keratinocytes. Bar¼ 100mm.
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adnexal structures. Intense immunostaining was evident in the
epidermal and dermal part of the eccrine sweat gland ducts.
The secretory portion of sweat glands showed staining in
single secretory and myoepithelial cells. Endothelial cells
decorating dermal blood vessels were also TRPV4 positive
(Figure 3). TRPA1 immunoreactivity was detected in the basal
layer of the epidermis in healthy skin (Figure 4). Specificity of
staining is indicated from previous studies (Nassini et al.,
2012; Sulk et al., 2012) and from negative controls performed
in the presence of an excess of the respective immunizing
peptide (Supplementary Figure S1 online).
Differential expression of TRPs in skin cancer tissues
Immunohistochemistry was used to determine semiquantita-
tively the level of expression of TRPV1, TRPV2, TRPV3,
TRPV4, and TRPA1 in keratinocytes of healthy skin and
cancer skin samples. As the expression of all the channels
was predominant in keratinocytes, the analysis was limited to
this cutaneous cell type. TRPV1, TRPV2, and TRPV3 expres-
sion was similar in atypical keratinocytes of SK, BD, SCC,
BCC, and in keratinocytes of healthy skin (Figure 1 and
Figure 2a and b). However, analysis of TRPV4 staining showed
from remarkable reduction to complete abrogation of protein
expression in skin samples of BD, SCC, and BCC of different
histotypes as compared with healthy skin samples (Figure 3a
and b). Reduction in TRPV4 protein staining was detected in
keratinocytes in all the tested conditions. In contrast, other
cells, such as those of the sweat gland ducts in the various
types of cancers, exhibited a TRPV4 staining intensity,
unchanged as compared with that observed in control samples
(as an example, see SCC in Figure 3). In SK samples, the
apparently reduced expression of TRPV4 staining did not
HS
HS SK SCC
BD Nod BCC
Nod BCC
Scl BCC
Scl BCC
TR
P
V
2 
in
te
ns
ity
 (s
co
re
) 5
4
3
2
1
0
Sup BCC
BCC
HS SK BD SCC Nod Sup Scl
TR
P
V
3 
in
te
ns
ity
3
5
4
2
1
0
BCC
HS SK BD SCC Nod Sup Scl
Figure 2. Localization of transient receptor potential vanilloid 2 and 3 (TRPV2 and TRPV3) in human healthy and cancer skin tissues. Immunohistochemical
localization reveals TRPV2 (a) and TRPV3 (b) protein staining in basal and suprabasal keratinocytes, endothelial cells, and neuronal structures. TRPV2 and TRPV3
staining and semiquantitative analysis of skin samples taken from patients suffering from solar keratosis (SK), Bowen’s disease (BD), squamous cell carcinoma
(SCC), and nodular (Nod), superficial (Sup), and sclerodermiform (Scl) basal cell carcinoma (BCC) do not show a significant difference in protein in atypical
keratinocytes. Bar¼ 100mm.
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reach the significance level (Figure 3a and b). In contrast,
expression of TRPA1 protein was significantly higher in SK as
compared with healthy skin, whereas no significant difference
was noted in any other skin cancer type (Figure 4). We further
tested TRPV4 messenger RNA (mRNA) expression by real-
time PCR in the same paraffin-embedded samples used for
immunohistochemical studies. Remarkable downregulation of
TRPV4 mRNA was observed in all the cancer types compared
with the level of TRPV4 mRNA measured in healthy skin
samples (Figure 3c). TRPV4 mRNA was detected in the whole
paraffin-embedded slice, and its decreased level paralleled the
decrease in protein staining observed in atypical or neoplastic
keratinocytes. As other cells (sweat gland cells) did not
show any reduction in TRPV4 protein, it is plausible that
keratinocytes from normal adnexal structures contribute only
marginally to the bulk of channel mRNA in the present human
skin tissues.
Inflammatory mediators downregulate TRPV4 mRNA expression
Several cytokines have been shown to contribute to the
biology of skin neoplasms, including BCC and SCC (Elamin
et al., 2008). Keratinocytes in response to different stimuli,
including UVB radiation, may release additional proinflam-
matory mediators such as prostaglandin E2 (PGE2), which has
been proposed to promote skin tumor development (Pei et al.,
1998; Countryman et al., 2000). The expression of TRPV4
(Becker et al., 2005) and TRPV1 (Southall et al., 2003)
channels in HaCaT has been previously reported. Moreover,
stimulation of HaCaT cells with the selective TRPV1 agonist,
capsaicin, caused the release of IL-8 (Southall et al., 2003).
By using western immunoblotting and real-time PCR, we
confirmed TRPV4 expression in the HaCaT cell line
(Figure 5a). Human embryonic kidney 293 and human
bronchial smooth muscle cells have been used as negative
and positive control (Jia et al., 2004), respectively (Figure 5a).
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Figure 3. Transient receptor potential vanilloid 4 (TRPV4) protein and messenger RNA (mRNA) results downregulated in different premalignant and invasive
non-melanoma skin cancers of different histotypes compared to human healthy skin. (a) Immunohistochemical localization reveals TRPV4 protein staining
in basal and suprabasal epidermal keratinocytes, and in adnexal structures in samples of healthy skin. TRPV4 staining (a) and semiquantitative analysis
(b) of skin samples taken from patients suffering from solar keratosis (SK), Bowen’s disease (BD), squamous cell carcinoma (SCC), and nodular (Nod), superficial
(Sup), and sclerodermiform (Scl) basal cell carcinoma (BCC) show a significant downregulation of protein in atypical keratinocytes. (c) TRPV4 mRNA analysis of
samples taken from SK, BD, SCC, and BCC (Nod, Sup, and Scl) paraffin-embedded tissues shows a significant downregulation of TRPV4 mRNA compared
with healthy skin (HS). Samples of dermatitis (inflamed tissues, IT) show levels of TRPV4 mRNA similar to those of HS. Values are expressed as percentage
compared with 18S mRNA. *Po0.05 versus HS (nonparametric, two-tailed Mann–Whitney test in b and analysis of variance (ANOVA) followed by Bonferroni’s
post hoc test in c). Bar¼100mm.
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Expression of TRPV4 in HaCaT cells was downregulated by
incubation for 24 hours with IL-8, IL-1b, tumor necrosis factor-
a (TNF-a), or PGE2 (Figure 5b–d).
IL-8 release and TRPV4 downregulation
To investigate the role of TRPV4 in the regulation of proin-
flammatory mediators in keratinocytes, we measured the
release of IL-8, IL-1b, TNF-a, and PGE2 from HaCaT cells
after exposure to the selective TRPV4 agonist 4a-phorbol-
12,13-didecanoate (4aPDD). 4aPDD evoked a concentration-
dependent release of IL-8 (Figure 5e). The response to 4aPDD
was abrogated in the presence of the TRPV4-selective antago-
nist HC-067047 (Everaerts et al., 2010; Figure 5e). In contrast,
exposure of HaCaT to 4aPDD (1–3–10mM) did not affect the
release of IL-1b, TNF-a, and PGE2 (Figure 5g–i). In addition to
4aPDD, we tested the effect of a highly selective and potent
TRPV4 agonist GSK1016790A (GSK; Thorneloe et al., 2008).
Exposure of HaCaT to GSK (0.5–1–5mM) produced a
concentration-dependent increase in IL-8 release, an effect
abated in the presence of HC-067047 (Figure 5f). Overnight
exposure to 4aPDD or to GSK (10 or 5mM, respectively) did
not affect cell viability (Figure 5j and k).
On the basis of these results, to investigate the possible
relationship between TRPV4 downregulation and IL-8, we
have measured the IL-8 mRNA level in healthy skin and tumor
tissues by real-time PCR. In addition, we included in this part
of the study some tissues characterized by neutrophilic
inflammation (pustular psoriasis, neutrophilic folliculitis, and
leucocytoclastic vasculitis) where presumably IL-8 should be
increased. In these samples, we measured mRNA for TRPV4
and IL-8 (Figure 5l). As expected, IL-8 mRNA expression was
high in inflamed tissues, whereas it was totally absent in
normal skin (Figure 5l). TRPV4 expression was similarly
elevated in both inflamed and normal skin (Figure 3c). SK,
BD, and malignant cancer samples exhibited variable levels of
IL-8 expression, between the almost undetectable value of
normal skin and the high level of inflamed tissues (Figure 5l).
DISCUSSION
In line with previous reports that described the distribution of
certain TRP proteins in epidermal keratinocytes in human skin
(Chung et al., 2003; Bodo et al., 2005; Atoyan et al., 2009;
Axelsson et al., 2009; Earley et al., 2010; Radtke et al., 2011),
we confirmed that in human healthy skin samples TRPV1,
TRPV2, TRPV3, TRPV4, and TRPA1 proteins are expressed in
basal and suprabasal epidermal keratinocytes. For TRPV4
protein, we also observed an intense staining in adnexal struc-
tures in the eccrine sweat gland ducts, myoepithelial cells, and
endothelial cells. Previous studies established an altered expres-
sion and function of one or more TRP proteins belonging to
different channel subfamilies in malignant cells of various types
of cancers. For instance, expression levels of members of the
TRP melastatin (Duncan et al., 2001; Tsavaler et al., 2001;
Oancea et al., 2009) and TRPV (Fixemer et al., 2003; Lazzeri
et al., 2005; Bode et al., 2009; Santoni et al., 2012) subfamilies
have been proposed to be associated with the induction/
progression of the different tumors. Thus, it is possible that in
human skin, and particularly in keratinocytes, thermo-TRPs may
undergo changes during the carcinogenesis process.
Here, we provide evidence that in skin samples obtained
from biopsies of premalignant lesions of NMSC, such as SK
and BD, and in malignant BCC and SCC, among the series of
TRPs analyzed, TRPA1 protein expression was increased in SK
and, more importantly, TRPV4 protein displays a remarkably
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Figure 4. Localization of transient receptor potential ankyrin 1 (TRPA1) in human healthy and cancer skin tissues. Immunohistochemical localization of
TRPA1 reveals protein staining in the basal layer of the epidermis in healthy skin. TRPA1 semiquantitative analysis of skin samples taken from patients suffering
from solar keratosis (SK), Bowen’s disease (BD), squamous cell carcinoma (SCC), and nodular (Nod), superficial (Sup), and sclerodermiform (Scl) basal cell
carcinoma (BCC) show a significant increase in TRPA1 staining only in atypical keratinocytes in samples of SK, whereas in different cases of BD, SCC, and BCC,
irrespective of different histotypes, TRPA1 expression does not display any significant difference in staining compared with healthy skin (HS). *Po0.05 versus
HS (nonparametric, two-tailed Mann–Whitney test). Bar¼ 100mm.
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reduced expression in skin cancer. Immunohistochemical
findings are strengthened by real-time PCR results. Remark-
able downregulation of the TRPV4 mRNA was found in the
same samples of skin cancer where TRPV4 protein expression
was also reduced. These results indicate that, regardless of the
initiating mechanism, TRPV4 downregulation occurs already
at the transcriptional level. The observation that such a
marked reduction, observed in cancer samples, also occurs
in a precancer condition such as SK suggests that epigenetic or
other factors that govern channel downregulation act similarly
in both atypical and malignant skin phenotypes.
Skin carcinogenesis has been associated with UV irradiation
and the ensuing increase in oxidative stress (Mukhtar and
Elmets, 1996), and TRPA1 exhibits a peculiar sensitivity for
oxidative stress by-products (Trevisani et al., 2007; Andersson
et al., 2008; Materazzi et al., 2008; Sawada et al., 2008). UV
radiation represents the major causative factor for melanoma
(Boniol et al., 2012; Mulliken et al., 2012). Increasing informa-
tion is available regarding the ability of UV to activate TRPA1.
A previous study has shown that, in a TRPA1-expressing
recombinant system, UVA, most probably via the generation
of reactive oxygen species, induces channel activation (Hill
and Schaefer, 2009). More recently, it has been reported that
UVA radiation stimulates TRPA1 in melanocytes, thus suggest-
ing a role for the TRPA1 channel in the phototransduction
process in melanocytes, and possibly in melanin synthesis
(Bellono et al., 2013). TRPA1 has also been detected in human
keratinocytes, where it modulates the expression of an array of
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Figure 5. Effect of proinflammatory mediators on transient receptor potential vanilloid 4 (TRPV4) messenger RNA (mRNA) expression and release of IL-8 by
TRPV4 stimulation in human keratinocytes. The protein levels of TRPV4 have been determined by western blot in different cellular lines including the human
keratinocyte cell line HaCaT (a) compared with human embryonic kidney 293 (HEK293) and human bronchial smooth muscle cells (HBSMCs) as negative and
positive control, respectively. Overnight exposure to increased concentrations (0.1–10 ng ml1) of IL-8 (b) and IL-1b (c) induces a significant reduction in the
TRPV4 mRNA levels in HaCaT. Values are expressed as percentage compared with 18S mRNA. A statistically significant reduction in TRPV4 mRNA level has also
been obtained after incubation of HaCaT cells with 10 ng ml1 TNF-a and 10mg ml 1 prostaglandin E2 (PGE2) (d). Each column represents the mean±SEM of at
least four independent experiments. *Po0.05 versus control group (Ctl) (analysis of variance (ANOVA) followed by Bonferroni’s post hoc test). Overnight exposure
to 4a-phorbol-12,13-didecanoate (4aPDD) (e) and GSK1016790A (GSK) (f) induces IL-8 release from HaCaT in a concentration-dependent manner. IL-8 release
evoked by both TRPV4 agonist 4aPDD (10mM) and GSK (5mM) is reduced by pretreatment with the selective TRPV4 antagonist HC-067047 (HC, 10mM). Overnight
exposure to 4aPDD did not increase the release of IL-1b (g), TNF-a (h), and PGE2 (i). Each column represents the mean±SEM of at least three independent
experiments. *Po0.05 versus basal group; yPo0.05 versus 4aPDD (10mM) and versus GSK (5mM). Effect of 4aPDD and GSK exposure on cell viability evaluated by
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test in HaCaT (j, k). Each column represents the mean±SEM of at least three
independent experiments. *Po0.05 versus basal group (Bas) (ANOVA followed by Bonferroni’s post hoc test). (l) Real-time PCR for the measurement of IL-8 mRNA
has been performed in the healthy skin (HS), solar keratosis (SK), Bowen’s disease (BD), squamous cell carcinoma (SCC), and nodular (Nod), superficial (Sup), and
sclerodermiform (Scl) basal cell carcinoma (BCC), as well as in samples of dermatitis (inflamed tissues, IT). Values are expressed as percentage compared with 18S
mRNA. *Po0.05 versus HS, ANOVA followed by Bonferroni’s post hoc test.
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genes involved in cell differentiation, metabolism, signaling,
and transcription (Atoyan et al., 2009). As SK is a condition
that is markedly associated with sun exposure, further research
may explore whether UV radiation is responsible for the
upregulation of TRPA1 in SK keratinocytes. However, a very
recent study reported that, at variance with TRPV4, in both
human and mouse skin samples local transcription of TRPA1
is not detectable (Liu et al., 2013).
However, the major finding of the present study relates to
TRPV4. Transformation from healthy to atypical, but not yet
malignant, keratinocytes in SK was associated with a tendency
(which, however, did not reach the significance level) to a
reduced TRPV4 expression, which, however, was fully evident
and significant in BD and in malignant forms of cancer such as
SCC. This suggests a sort of progressive reduction in TRPV4
protein expression from healthy to precancerous and finally
malignant skin cancer phenotypes. The implications of the
present results are 2-fold. First, we confirm that in human skin
TRPV4 expression is not solely confined to cutaneous
nociceptors, but it is abundantly distributed in different non-
neuronal cutaneous cell types, and prevalently in keratino-
cytes. Second, loss of TRPV4 expression in keratinocytes
seems to be specifically associated with the transition from a
healthy phenotype to a cancer phenotype. TRPV4 has been
claimed to produce various functions in keratinocytes.
Although keratinocyte TRPV4 may respond to warm tempera-
tures (Chung et al., 2003), TRPV3 appears to mainly contribute
to the transmission of warm temperature sensation, via ATP
release in these cells (Mandadi et al., 2009). Additional
proposed roles of TRPV4 in keratinocytes are represented by
the control of the skin permeability barrier (Denda et al.,
2007), and the promotion of Ca2þ -dependent phenomena as
the development and maturation of cell–cell junctions (Sokabe
et al., 2010). Cell proliferation and differentiation are
regulated by Ca2þ ions, as high extracellular Ca2þ favors
differentiation and low extracellular Ca2þ maintains an
undifferentiated state. It is possible that the TRPV4 channel
contributes to these phenomena in keratinocytes (Lee and
Caterina, 2005). A recent paper has reported that UVB
exposure causes direct TRPV4 activation in keratinocytes,
and that epidermal TRPV4 orchestrates UVB-evoked skin
tissue damage, thus increasing the expression of the proal-
gesic mediator, endothelin-1, and producing pain behavior in
mice; all these effects were reduced by TRPV4 inhibition
(Moore et al., 2013). In addition, also in human specimens,
the expression of epidermal TRPV4 and endothelin-1 is
enhanced by sunburn (Moore et al., 2013). Together, these
data strongly highlight the role of TRPV4 expressed in
keratinocytes as a therapeutic target for UVB-evoked skin
tissue damage and sunburn-related pain.
It has been widely reported that both cancer cells and
surrounding cells release a wide array of cytokines in order to
establish a tumor microenvironment that affects cancer cell
growth differently, attenuating apoptosis and promoting tissue
invasion and metastasis (Elamin et al., 2008; St John et al.,
2009). Several proinflammatory and immunomodulatory
cytokines are induced in epidermal cells after exposure to
one of the most prominent cutaneous tumorigenic agents, UV
radiation, including IL-1b, IL-6, IL-8, and TNF-a (Kupper et al.,
1987; Takashima and Bergstresser, 1996; Strickland et al.,
1997). TNF-a mediates UV induction of adhesion molecule
expression (Krutmann et al., 1992) and Langerhans cell
migration (Vincek et al., 1993). IL-8 is a chemokine that
induces an inflammatory cell infiltrate after UV radiation
(Strickland et al., 1997); IL-1b acts as a chemoattractant,
induces TNF-a (Corsini et al., 1995), and enhances keratino-
cyte prostaglandin synthesis (Pentland and Mahoney, 1990);
and one prostaglandin, PGE2, increases in epidermal keratino-
cytes after UV irradiation (Rundhaug et al., 2011). To explore
the mechanism responsible for the marked reduction in
TRPV4 expression in tumor keratinocytes, we measured
channel mRNA expression in a keratinocyte cell line
(HaCaT cells) which has been reported to express TRPV4
(Becker et al., 2005) by real-time PCR, after exposure to IL-1b,
IL-6, IL-8, and TNF-a and PGE2. All these stimuli induced a
dose-dependent reduction in TRPV4 mRNA levels, thus
suggesting that cytokines and prostaglandins, released within
the tumor milieu, have the potential to reduce or suppress
TRPV4 gene expression in keratinocytes. Next, we explored
the ability of TRPV4 to release the proinflammatory mediators
that downregulate channel expression. Present data demon-
strate that TRPV4 stimulation by the selective agonist 4aPDD
did not affect the release of IL-1b, TNF-a, and PGE2 from
HaCaT cells. However, TRPV4 stimulation by 4aPDD
increased IL-8 release, which should be specifically dependent
on channel activation, as it was abrogated by the selective
TRPV4 antagonist HC-067047. Previous studies have reported
that TRP channel stimulation causes IL-8 release. TRPV1
stimulation has been shown to release IL-8 from HaCaT
cells (Southall et al., 2003), and it modulates IL-8 release in
human corneal epithelial cells (Wang et al., 2011). Recently,
we reported that TRPA1 activation releases IL-8 from TRPA1
expressed in non-neuronal airway cells (Nassini et al., 2012).
IL-8 release can be considered as part of a defense response
orchestrated by keratinocytes, via TRPV4, to limit cancer
progression. However, it is also possible that IL-8, down-
regulating TRPV4, may progressively reduce keratinocyte
potential to release IL-8 itself. To better address this issue,
we studied the expression of IL-8 mRNA in healthy skin and
cancer tissues and both IL-8 and TRPV4 mRNA in skin
dermatitis biopsies. The observation that, in inflamed tissues,
IL-8 mRNA was, as expected, elevated, and TRPV4 expression
was high and comparable to that of normal skin, indicates that
increased IL-8 levels do not warrant TRPV4 downregulation.
Thus, the most parsimonious explanation is that the marked
reduction in TRPV4 expression documented in skin cancers is
independent from, and not the consequence of, the variable
and moderate increase in IL-8 observed in these conditions.
A constraint of the present study is represented by the
limited number of cases analyzed, a factor that may under-
estimate differences in TRPV1, TRPV2, TRPV3, and TRPA1
expression in the various types of cancer. Nevertheless, our
findings, showing a remarkable channel downregulation,
point to TRPV4 as an early biomarker of cutaneous cancers.
The ability of IL-8 to downregulate TRPV4 and of TRPV4 to
release IL-8 depict a possible autocrine circuitry carried out by
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keratinocytes to regulate skin homeostasis and contribute to
pathophysiological events. However, the observation that
TRPV4 expression is not affected by high IL-8 levels, as found
in inflamed tissues, strengthens the hypothesis that TRPV4 is
upstream to IL-8 and not vice versa. An additional hypothesis
is that the remarkable TRPV4 downregulation in cancer, a
condition that is most likely associated with cancer onset and
progression, may contribute to a poor defensive inflammatory
response in skin cancer.
MATERIALS AND METHODS
Tissue collection
The study series included skin biopsies of human healthy skin (n¼ 4),
SK (n¼ 5), BD (n¼ 5), invasive cutaneous SCC (n¼ 7), and BCC of
different histotypes, including nodular (n¼ 4), superficial (n¼ 5), and
sclerodermiform/morphea-like types (n¼ 3). To examine the expres-
sion of mRNA of TRPV4 and IL-8 skin biopsies of pustular psoriasis
(n¼ 3), neutrophilic folliculitis (n¼ 3) and leucocytoclastic vasculitis
(n¼ 3) were also included in the study. Paraffin-embedded skin
specimens were retrospectively retrieved from the archive of the
Division of Pathology, Department of Surgery and Translational
Medicine, the University of Florence, Italy. Patients’ data, including
age, sex, and anatomic tumor site, were collected. The median age of
patients with SK and BD was 67 (range, 53–79) and 73.3 (range,
71–81) years, respectively. For both premalignant lesions, three
patients were female and two patients were male. Tumor site
distribution was the head and neck, upper extremities, and trunk.
The median age of patients with SCC was 80 years (range 73–88
years). Six patients were male and one was female, and the tumor site
distribution was upper extremities. The median age of patients with
nodular BCC was 71 years (range, 39–89 years), eight patients were
male and four were female, and the tumor site distribution was upper,
lower, and trunk extremities. Ethical approval for the experiments
performed on human tissue was obtained from the internal institu-
tional review board.
Immunohistochemistry
Sections of 4-mm thickness were cut from tissue blocks of formalin-
fixed, paraffin-embedded samples. Immunostaining was performed
according to standard procedures. In brief, antigen retrieval was
routinely performed by immersing the slides in a thermostat bath
containing 10 mM citrate buffer (pH 6.0) for 15 min at 97 1C followed
by cooling for 20 minutes at room temperature. Endogenous perox-
idase activity was blocked with 3% hydrogen peroxide in distilled
water for 10 minutes. After blocking with normal horse serum
(UltraVision, Bio-Optica, Milan, Italy), sections were incubated over-
night at 4 1C with the following rabbit polyclonal antibodies: TRPV1
(1:100, Abcam, Cambridge, UK), TRPV2 (1:200, Acris Antibodies
Herford, Germany), TRPV3 (1:100 Acris Antibodies), TRPV4 (1:50,
Sigma-Aldrich, Milan, Italy), and TRPA1 (1:250, Novus Biologicals,
Cambridge, UK). Bound antibodies were visualized using aminoethyl-
carbazol as chromogen (Bio-Optica). Nuclei were counterstained
with Mayer’s hematoxylin. Negative controls were performed by
preadsorption with immunizing peptide (overnight 4 1C) for all the
antisera. For the semiquantitative image analysis, epidermal intensity
and area of immunostained cells were rated on a scale of 0–4
(0 absent, 1 weak/low, 2 moderate, 3 strong, and 4 very strong
staining).
Cell culture
The human keratinocyte cell line HaCaT (Cell Line Service, Eppelheim,
Germany), human bronchial smooth muscle cell (PromoCell,
Heidelberg, Germany), and human embryonic kidney cell 293
(American Type Cell Collection, Manassas, VA) were grown in DMEM
supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 U ml 1 penicillin, and 100mg ml 1 streptomycin (Sigma-Aldrich).
Cells were cultured in an atmosphere of 95% air and 5% CO2 at 37 1C.
Measurement of cytokines and PGE2 production by keratinocyte
cell culture
Cells were plated at a density of 200,000 cells per well in a 24-well
plate and grown for 24 hours to B80–90% confluence, and then
exposed to different concentrations (1–30mM) of the selective TRPV4
agonist, 4aPDD (Sigma-Aldrich), or its vehicle (0.3% DMSO), in a
serum-free medium. In a different set of experiments, HaCaT cells
were exposed to GSK (0.5, 1, 5, 10mM), another potent and selective
TRPV4 agonist (Thorneloe et al., 2008), or its vehicle (0.5% DMSO).
Selective TRPV4 antagonist HC-067047 (10mM; Everaerts et al., 2010;
Tocris Bioscience, Bristol, UK), or its vehicle (0.1% DMSO), was
added 30 minutes before exposure to the agonists. The medium was
collected 18 hours after treatment, and human IL-8, IL-6, IL-1b, (TNF-
a), and prostaglandin E2 (PGE2) were measured using the commercial
quantitative ELISA kit (Invitrogen, Carlsbad, CA).
Western immunoblot assay
HaCaT, human bronchial smooth muscle cells, and human embryo-
nic kidney 293 cells were lysed for 30 minutes at 4 1C in a buffer
containing 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EGTA, 100 mM
NaF, 1 mM Na3VO4, 1% Nonidet P40, and complete protease
inhibitor cocktail (Roche, Mannheim, Germany). Cell lysates were
used for the TRPV4 protein detection, as described in detail in
Supplementary Materials and Methods online.
Reverse transcriptase–PCR and real-time PCR
Extraction of mRNA was performed in paraffin-embedded tissues as
described (Kalmar et al., 2013), with some modification. In brief,
deparaffinization was performed by adding 1 ml of xylene for
10 minutes twice and 1 ml absolute ethanol for 10 minutes twice.
Total RNA has been extracted from the air-dried deparaffinized
sections by using the TRIZOL method (Invitrogen).
HaCaT, human bronchial smooth muscle cells, and human
embryonic kidney 293 cells were seeded in six-well plates and
grown for 24 hours to 90% confluence before stimulation or mRNA
extraction. Then, cells were exposed for 24 hours, in a serum-free
medium, to different concentrations of several inflammatory media-
tors, including IL-8, IL-1b, IL-6, TNF-a (all 0.1–10 ng ml 1), and
PGE2 10mg ml 1, or their vehicles (cell medium without stimulus).
Total cellular RNA was extracted from stimulated and unstimulated
cells by using the TRIZOL method (Invitrogen). Complementary DNA
was prepared from total RNA using the iScript cDNA Synthesis kit
(Bio-Rad, Milan, Italy), and the real-time PCR was performed to check
the TRPV4 and IL-8 mRNA levels as described in more details in
Supplementary Materials and Methods online.
Vitality assay by the tetrazolium salt method (MTT reduction assay)
Cytotoxicity of various stimuli, including 4aPDD, GSK, or inflamma-
tory mediators tested on HaCaT cell line, was assessed by using the
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MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
viability test, as described in detail in Supplementary Materials and
Methods online.
Statistical analysis
For the semiquantitative image analysis, statistical significance was
determined by using a nonparametric one-way analysis of variance
followed by the Kruskal–Wallis post hoc test. All other data are
presented as mean±SEM. Statistical significance was determined by
using one-way analysis of variance, followed by Bonferroni’s post hoc
analysis for comparison of multiple groups. Po0.05 was considered
significant.
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